XBIOME
Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. The company uses artificial intelligence to analyze patient and donor intestinal (gut) flora to more quickly develop effective pharmaceuticals.
XBIOME
Industry:
Artificial Intelligence Biotechnology Medical Pharmaceutical
Founded:
2017-01-01
Address:
Shenzhen, Guangdong, China
Country:
China
Website Url:
http://www.xbiome.cn
Total Employee:
11+
Status:
Active
Contact:
0755-86530994
Total Funding:
124.21 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apache Mobile Non Scaleable Content Euro Amazon Microsoft Azure DNS PHP
Similar Organizations
Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Proscia
Proscia develops a pathology platform to assist routine pathology operations, enhance cancer diagnosis, and improve patient outcomes.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
Founder
Investors List
Sky9 Capital
Sky9 Capital investment in Series B - Xbiome
Primavera Capital Group
Primavera Capital Group investment in Series B - Xbiome
Hike Capital
Hike Capital investment in Series B - Xbiome
Wuyuan Capital
Wuyuan Capital investment in Series B - Xbiome
Legend Capital
Legend Capital investment in Series B - Xbiome
Tiantu Capital
Tiantu Capital investment in Series B - Xbiome
5Y Capital
5Y Capital investment in Series B - Xbiome
Gaorong Capital
Gaorong Capital investment in Series B - Xbiome
Legend Capital
Legend Capital investment in Funding Round - Xbiome
Gaorong Capital
Gaorong Capital investment in Funding Round - Xbiome
Official Site Inspections
http://www.xbiome.cn
- Host name: ec2-18-140-237-150.ap-southeast-1.compute.amazonaws.com
- IP address: 18.140.237.150
- Location: Singapore Singapore
- Latitude: 1.2929
- Longitude: 103.8547
- Timezone: Asia/Singapore
- Postal: 18
More informations about "Xbiome"
Xbiome - Crunchbase Company Profile & Funding
Xbiome.cn/ 29,879; Highlights. obfuscated. Total Funding Amount . Unlock for free . Contacts 9. Employee Profiles 2. Investors 12. Similar Companies 13. Recent News & Activity. ... Xbiome is the first AI pharmaceutical company in …See details»
Xbiome - 未知君 - 解开微生态奥秘，守卫人类健康
未知君是国内行业领先的ai微生物组研究和产业转化平台，旨在通过配方菌、基因工程微生物等微生态治疗方式，实现肠道及其他系统性疾病的缓解或治疗。未知君将人工智能与肠道微生物技 …See details»
关于我们 - 领先的AI微生物组研究和产业转化平台
邮箱：[email protected] 团队介绍 未知君拥有复合型的研究团队和资深、专业的临床开发团队，具备国际领先技术及先进视野，可以快速打通药物开发、临床应用、临床申报各个环节，实现跨学科、跨产业的深度互补，将最前沿认知迅速 …See details»
Xbiome - LinkedIn
Shenzhen, Guangdong, CN Get directions New York, New York 10003, US Get directions ... Xbiome Co., Ltd. is dedicated to gut microbiome using AI techniques, and committed to the gut …See details»
Org Chart Xbiome - The Official Board
The organizational chart of Xbiome displays its 3 main executives including Yan Tan. Toggle navigation The Official Board. Search. Search. Search by segment. Sign In. Business E-mail* …See details»
Xbiome Overview | SignalHire Company Profile
The position of the Co-Founder & CEO is occupied by Yan Tan. Its headquarters is located at Shenzhen, Guangdong Province, CN. The number of employees ranges from 25 to 100. The …See details»
Xbiome | 领英 - 领英 (中国)
Xbiome | 在领英上有 1,392 位关注者。中国业内领先的专注于肠道微生态治疗的 AI 制药公司 | 未知君是国内领先的专注于肠道微生态治疗的AI制药公司，致力于以肠道微生态为基础，以AI技 …See details»
Xbiome - Company Profile & Staff Directory - ContactOut
As the leading AI-based microbiome drug development company in China, Xbiome Co., Ltd. is dedicated to gut microbiome using AI techniques, and committed to the gut health of human …See details»
Xbiome Company Profile 2024: Valuation, Funding & Investors
Xbiome General Information Description. Developer of microbial pharmaceuticals designed to treat microecological intestinal disorders. The company uses artificial intelligence to analyze …See details»
Xbiome Company Profile - Office Locations, Competitors, Revenue …
Xbiome has 5 employees across 5 locations. See insights on Xbiome including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Xbiome - Org Chart, Teams, Culture & Jobs | The Org
View Xbiome's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. Explore. Iterate. Vision. Log in. Sign up. …See details»
Xbiome Information - RocketReach
Xbiome.cn; xbiome.com; 2 530752XXXX; 415801XXXX; Shulin Wang Chief Medical Science Advisor at Xbiome Shenzhen, Guangdong Province, CN View. 1 gmail.com; 1 609818XXXX; …See details»
Shenzhen Xbiome Biotech Co., Ltd. - cnverify.com
Email: **[email protected] View Full Email. Shenzhen Xbiome Biotech Co., Ltd. Employees: 0-100 Detail ( 72.48% of companies have fewer than 5 employees. ) Registered …See details»
Xbiome - Company info. interviews, news - BiopharmaTrend
Mar 18, 2020 Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to …See details»
Xbiome - Golden
Xbiome. Chinese microbiome artificial intelligence drug discovery platform founded in 2017 by Yan Tan. Overview Structured Data Issues Contributors Activity. Contents. xbiome.cn. Is a. …See details»
Xbiome (未知君) Company Profile: Funding, Investors & Partnerships
Oct 15, 2022 Unlike the traditional paradigm of drug discovery, Xbiome's approach innovatively combines microbial technologies, artificial intelligence, bioinformatics analysis and gut …See details»
Xbiome - Overview, News & Similar companies | ZoomInfo.com
Jan 28, 2022 Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xbiome Inc., an industry leading AI driven …See details»
Yan Tan – CEO, Xbiome, China - PharmaBoardroom
Jun 17, 2020 Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what makes its technology …See details»
Xbiome - Products, Competitors, Financials, Employees, …
Xbiome acquires drug from Assembly Biosciences to treat ulcerative colitis. May 3, 2022. May 3, 2022 Xbiome Inc. acquired M-201, a clinical-stage program from Assembly Biosciences Inc., …See details»
Xbiome - VentureRadar
" As the first AI-based microbiome drug development company in China, Xbiome Co., Ltd. is dedicated to gut microbiome using AI techniques, and committed to the gut health of 1.3 billion …See details»